Premium
O2‐03‐02: Amorfix Epitope Protection‐Alzheimer's Disease (EP‐AD) diagnostic cerebrospinal fluid test for accurate identification of Alzheimer's disease and mild cognitive impairment
Author(s) -
Scrocchi Louise,
Karaskov Elizabeth,
Chen Hui,
Lee Vivian,
Demers Ryan,
Yousefi Masoud,
Uger Marni,
Cashman Neil
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.635
Subject(s) - cerebrospinal fluid , biomarker , immunoassay , epitope , medicine , alzheimer's disease , receiver operating characteristic , disease , antigen , pathology , immunology , antibody , chemistry , biochemistry
major health and social care challenges for the 21st century worldwide. The global number of people with dementia was calculated at 36 million by 2010 and is estimated to increase to 66 million by 2030 and 115 million by 2050 (World Alzheimer Report 2009). The global cost is estimated at US$604 billion by 2010 (World Alzheimer Report 2010). Governments and societies are not prepared to these challenges. Therefore Alzheimer’s Disease International (ADI), the global federation of Alzheimer associations is campaigning to make dementia a global health priority with programs of World Health Organization (WHO) and United Nations (UN). Methods: ADI has started an advocacy program towards WHO and UN meetings including training of national advocates, creating an international network and visiting international and regional meetings and make statements, contact country representatives and produce data on prevalence and cost of illness. Results: Dementia was included in the Mental Health Global Action Programme of WHO as a priority area. The UN High Level Meeting on Non-Communicable Diseases in September 2011 adopted a paragraph on the importance of mental health and Alzheimer’s disease. The WHO is going to release a report Dementia: A Public Health Priority by April 2012. A resolution on ageing will be put forward at the annual WHO assembly in May 2012. Conclusions: Alzheimer’s disease and dementia have become part of the international health agenda. This needs to be implemented in national and subnational action plans. This has happened in a few countries like Australia, Korea, France and England. A plan for the USA is on its way. Monitoring and evaluation of those plans will be crucial as well as securing the funding. Countries without a plan need to be encouraged to develop.